For the fourth time this month, U.K. authorities have opened a new investigation into an unspecified number of drug makers over potential violations of anti-competitive laws concerning generic drugs.

The U.K. Competition and Markets Authority opened the probes into “various parties” regarding “suspected abuse” into “certain generic” medicines, according to statements on the agency web site. The latest probe was opened on Wednesday, while the other three investigations began on Oct. 10. Further details were not disclosed.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy